Get the latest Alexion Pharmaceuticals, Inc. (ALXN) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.
Get the latest IHS Markit Ltd. (INFO) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.
Investing in Zoom Shares – Final Thoughts In some respects, Zoom exemplifies the mood of uncertainty that grips the markets right now, as the economic fallout of the Coronavirus crisis remains unclear. The company has undoubtedly been one of the pandemic’s biggest success stories, but it’s ...
You don’t need any prior investment experience – nor do you need to know how to set up complex buy and sell positions. Instead, you simply need to search for the stock that you want to buy and determine the size of your investment. What we also like about Robinhood is that you can...
SoFi Technologies (NASDAQ: SOFI) reported a beat on top and bottom lines and raised guidance this morning. What happened to SoFi stock, and is this rocket-fueled rally justified? The video below breaks it down and provides earnings, analysis, valuation metrics, and commentary. Don't ...
Its shares are up nearly 5% in 2024 and down 9% over the past five years. Of the three, Supernus is the one I’m not at all familiar with. The company has over 30 years of experience with CNS (central nervous system) drugs, including four products for ADHD (attention deficit...
All shares are much higher risk than cash or bonds, and you can lose all your money. That said, the following look good opportunities for more risk-averse equity investors. Tesco You can now buy Tesco at around the same price Warren Buffett paid when he first bought into the supermarket ...
Also, Arcus is partnering withAstraZeneca(NASDAQ:AZN) for developing a combo therapy for lung cancer. The second half of the year is a catalyst-rich one for the biotech, with several clinical readouts scheduled for the period. Arcus stock is down over 20% in the year-to-date....
The board figured Tesaro had several options. It could sign a codevelopment and copromotion deal with a bigger company. It could do a royalties deal to bring in cash. It could do a deal for rights outside the U.S. and Europe, or perhaps sell securities. ...
“I think we are still very much in the foothills of oncology but what is striking is that these things can change very quickly,” Miels said, pointing to the rapid success of his former employer AstraZeneca. Analysts have been predicting a boom in pharmaceutical industry mergers and acquisitio...